慢性可诱导性荨麻疹的治疗进展

doi:10.35541/cjd.20210677

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1110-1113.doi: 10.35541/cjd.20210677

慢性可诱导性荨麻疹的治疗进展

陈奇权宋志强

陆军军医大学西南医院皮肤科，重庆 400038

收稿日期:2021-09-15 修回日期:2021-10-11 发布日期:2021-12-01
通讯作者: 宋志强 E-mail:drsongzq@qq.com
基金资助:
国家自然科学基金（82003359）

Treatment of chronic inducible urticaria

Chen Qiquan, Song Zhiqiang

Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing 400038, China

Received:2021-09-15 Revised:2021-10-11 Published:2021-12-01
Contact: Song Zhiqiang E-mail:drsongzq@qq.com
Supported by:
National Natural Science Foundation of China（82003359）

摘要/Abstract

摘要： 【摘要】慢性可诱导性荨麻疹（CIndU）的发病机制目前尚未完全清楚，仅仅靠针对诱因的规避常常无法达到满意的症状控制效果。近年来国内外在CIndU的治疗方面取得一定进展，如传统的抗组胺药、非抗组胺药、生物制剂及小分子靶向药等药物治疗，以及诱因脱敏治疗等物理治疗等，本文对这些进展进行全面系统的梳理和总结。

关键词: 荨麻疹, 治疗, 组胺拮抗药, 生物制剂, 慢性可诱导性荨麻疹, 物理性荨麻疹

Abstract: 【Abstract】 At present, the pathogenesis of chronic inducible urticaria （CIndU） is not completely clear, and it is often difficult to achieve satisfactory symptom control only by avoiding triggers. In recent years, some progress has been made in the treatment of CIndU in China and other countries, such as traditional antihistamines, non-antihistamines, biological agents, small-molecule targeted drugs and other drug treatments, as well as physical therapies such as trigger-point desensitization therapy. This review comprehensively and systematically outlines and summarizes relevant progress.

Key words: Urticaria, Therapy, Histamine antagonists, Biological agents, Chronic inducible urticaria, Physical urticaria

陈奇权宋志强. 慢性可诱导性荨麻疹的治疗进展[J]. 中华皮肤科杂志, 2021,54(12):1110-1113. doi:10.35541/cjd.20210677

Chen Qiquan, Song Zhiqiang. Treatment of chronic inducible urticaria[J]. Chinese Journal of Dermatology, 2021, 54(12): 1110-1113.doi:10.35541/cjd.20210677

参考文献 37

［1］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［2］	Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1119⁃1130. doi: 10.1016/j.jaip.2018.03.007.
［3］	Maurer M, Hawro T, Krause K, et al. Diagnosis and treatment of chronic inducible urticaria［J］. Allergy, 2019,74（12）:2550⁃2553. doi: 10.1111/all.13878.
［4］	Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study［J］. J Dermatol Sci, 2017,87（1）:60⁃69. doi: 10. 1016/j.jdermsci.2017.02.283.
［5］	Pereira A, Motta AA, Kalil J, et al. Chronic inducible urticaria: confirmation through challenge tests and response to treatment［J］. Einstein （Sao Paulo）, 2020,18:eAO5175. doi: 10.31744/einstein_journal/2020ao5175.
［6］	Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management［J］. Clin Auton Res, 2018,28（1）:103⁃113. doi: 10. 1007/s10286⁃017⁃0418⁃6.
［7］	Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ what we know and what we do not know［J］. Allergy, 2021,76（4）:1077⁃1094. doi: 10.1111/all.14674.
［8］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd. 14543.
［9］	Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options［J］. J Allergy Clin Immunol, 2018,141（5）:1726⁃1734. doi: 10.1016/j.jaci.2018. 01.031.
［10］	Cassano N, Mastrandrea V, Vestita M, et al. An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatment［J］. Dermatol Ther, 2009,22 Suppl 1:S22⁃S26. doi: 10.1111/j.1529⁃8019.2009.01268.x.
［11］	Morgado⁃Carrasco D, Fustà⁃Novell X, Podlipnik S, et al. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature［J］. Photodermatol Photoimmunol Photomed, 2018,34（3）:194⁃199. doi: 10.1111/phpp.12370.
［12］	Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options［J］. J Allergy Clin Immunol Pract, 2020,8（9）:3141⁃3161. doi: 10. 1016/j.jaip.2020.05.016.
［13］	Wang F, Zhao YK, Luo ZY, et al. Aquagenic cutaneous disorders［J］. J Dtsch Dermatol Ges, 2017,15（6）:602⁃608. doi: 10.1111/ddg.13234.
［14］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA（2） LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884.
［15］	Kozaru T, Fukunaga A, Taguchi K, et al. Rapid desensitization with autologous sweat in cholinergic urticaria［J］. Allergol Int, 2011,60（3）:277⁃281. doi: 10.2332/allergolint.10⁃OA⁃0269.
［16］	Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction［J］. Dermatology, 2012,224（2）:101⁃105. doi: 10.1159/000336572.
［17］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd. 14543.
［18］	Aguilera P. Inducing light tolerance with narrowband UV⁃B therapy in solar urticaria［J］. Actas Dermosifiliogr （Engl Ed）, 2018,109（10）:853. doi: 10.1016/j.ad.2018.06.009.
［19］	Takahagi S, Tanaka A, Hide M. Sweat allergy［J］. Allergol Int, 2018,67（4）:435⁃441. doi: 10.1016/j.alit.2018.07.002.
［20］	Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria［J］. J Am Acad Dermatol, 2000,42（6）:1030⁃1032. doi: 10.1016/s0190⁃9622（00）90299⁃8.
［21］	Gaebelein⁃Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: clinic, diagnostic, course and therapy management in 27 patients［J］. J Dtsch Dermatol Ges, 2020,18（11）:1261⁃1268. doi: 10. 1111/ddg.14309.
［22］	Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine⁃resistant symptomatic dermographism: a pilot study［J］. J Am Acad Dermatol, 2008,59（5）:752⁃757. doi: 10.1016/j.jaad.2008. 07.016.
［23］	Siiskonen H, Smorodchenko A, Krause K, et al. Ultraviolet radiation and skin mast cells: effects, mechanisms and relevance for skin diseases［J］. Exp Dermatol, 2018,27（1）:3⁃8. doi: 10. 1111/exd.13402.
［24］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［25］	宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗27例人工荨麻疹回顾分析［J］. 中华皮肤科杂志, 2021,54（12）:1092⁃1096. doi: 10.35541/cjd.20210473.
［26］	Boyce JA. Successful treatment of cold⁃induced urticaria/anaphylaxis with anti⁃IgE［J］. J Allergy Clin Immunol, 2006,117（6）:1415⁃1418. doi: 10.1016/j.jaci.2006.04.003.
［27］	Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence［J］. J Allergy Clin Immunol, 2018,141（2）:638⁃649. doi: 10.1016/j.jaci.2017.06.032.
［28］	Pressler A, Grosber M, Halle M, et al. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio⁃oedema［J］. Clin Exp Dermatol, 2013,38（2）:151⁃153. doi: 10. 1111/j.1365⁃2230.2012.04430.x.
［29］	Can PK, Salman A, Hoşgören⁃Tekin S, et al. Effectiveness of omalizumab in patients with chronic inducible urticaria: real⁃life experience from two UCARE centres［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:e679⁃e682. doi: 10.1111/jdv.17385.
［30］	Fialek M, Dezoteux F, Le Moing A, et al. Omalizumab in chronic inducible urticaria: a retrospective, real⁃life study［J］. Ann Dermatol Venereol, 2021:S0151⁃9638（21）00063⁃6. doi: 10. 1016/j.annder.2021.04.010.
［31］	Bodar EJ, Simon A, de Visser M, et al. Complete remission of severe idiopathic cold urticaria on interleukin⁃1 receptor antagonist （anakinra）［J］. Neth J Med, 2009,67（9）:302⁃305.
［32］	Gualdi G, Monari P, Rossi MT, et al. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis［J］. Br J Dermatol, 2012,166（6）:1373⁃1374. doi: 10. 1111/j.1365⁃2133.2011.10797.x.
［33］	Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti⁃TNF⁃alpha［J］. J Allergy Clin Immunol, 2007,119（3）:752⁃754. doi: 10.1016/j.jaci.2006. 12.658.
［34］	Ferrucci S, Benzecry V, Berti E, et al. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment［J］. Clin Exp Dermatol, 2020,45（3）:345⁃346. doi: 10.1111/ced.14081.
［35］	Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:e112⁃e113. doi: 10.1111/jdv.14594.
［36］	Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism［J］. J Eur Acad Dermatol Venereol, 2019,33（11）:e413⁃e415. doi: 10.1111/jdv.15720.
［37］	Dickson MC, Walker A, Grattan C, et al. Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a/b randomised double⁃blind placebo⁃controlled study［J］. Br J Clin Pharmacol, 2021 ［2021⁃09⁃01］. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp. 14923. doi: 10.1111/bcp.14923.

[1]	张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767.
[2]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.
[3]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[4]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[5]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[6]	王娟娟陈容季江苏文星魏钰倩赵莹尹兴平苏玉华施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234.
[7]	张婷婷朱凤仪杨梅张平夏萍周小勇. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210644-e20210644.
[8]	温广东冒丹丹张原媛窦沅青赵培吴晨雨张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694.
[9]	焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384.
[10]	王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115.
[11]	李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631.
[12]	欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184.
[13]	包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156.
[14]	郭静杨景煜丁黎刘明明侯晶梅蒲小霞孙嘉昱李向花. 长脉宽1 064 nm Nd：YAG激光联合含滇山茶和三七等提取物的外用乳剂治疗黄褐斑的疗效[J]. 中华皮肤科杂志, 2022, 55(1): 61-64.
[15]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）[J]. 中华皮肤科杂志, 2022, 55(1): 1-11.

慢性可诱导性荨麻疹的治疗进展

Treatment of chronic inducible urticaria

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

Metrics

本文评价

推荐阅读 10